• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    NervGen Pharma Corp. - Common stock (NQ:NGEN)

    1.680 +0.020 (+1.20%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 597,252
    Open 1.660
    Bid (Size) 1.650 (1,400)
    Ask (Size) 1.710 (300)
    Prev. Close 1.660
    Today's Range 1.640 - 1.750
    52wk Range 1.580 - 6.300
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    These stocks have an unusual volume in today's session ↗
    Via Chartmill
    News headline image
    NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study
    From NervGen Pharma Corp.
    Via GlobeNewswire

    Performance

    YTD
    -71.9%
    -71.9%
    1 Month
    -20.4%
    -20.4%
    3 Month
    -56.8%
    -56.8%
    6 Month
    -60.3%
    -60.3%
    1 Year
    -71.9%
    -71.9%

    More News

    Read More
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill
    Keep an eye on the top gainers and losers in Friday's session. ↗
    Via Chartmill
    Friday's session: gap up and gap down stocks ↗
    Via Chartmill
    Discover the top movers in Friday's pre-market session. ↗
    Via Chartmill
    News headline image
    NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
    From NervGen Pharma Corp.
    Via GlobeNewswire
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    NervGen Announces Proposed Public Offering of Securities
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma to Participate at Upcoming Investor Conferences
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
    From NervGen Pharma Corp.
    Via GlobeNewswire
    News headline image
    NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
    From NervGen Pharma Corp.
    Via GlobeNewswire

    Frequently Asked Questions

    Is NervGen Pharma Corp. - Common stock publicly traded?
    Yes, NervGen Pharma Corp. - Common stock is publicly traded.
    What exchange does NervGen Pharma Corp. - Common stock trade on?
    NervGen Pharma Corp. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for NervGen Pharma Corp. - Common stock?
    The ticker symbol for NervGen Pharma Corp. - Common stock is NGEN on the Nasdaq Stock Market
    What is the current price of NervGen Pharma Corp. - Common stock?
    The current price of NervGen Pharma Corp. - Common stock is 1.680
    When was NervGen Pharma Corp. - Common stock last traded?
    The last trade of NervGen Pharma Corp. - Common stock was at 08/05/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.